0001072613-05-000485.txt : 20120629
0001072613-05-000485.hdr.sgml : 20120629
20050223172010
ACCESSION NUMBER: 0001072613-05-000485
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20050223
DATE AS OF CHANGE: 20050223
GROUP MEMBERS: ABINGWORTH BIOVENTURES III A L.P.
GROUP MEMBERS: ABINGWORTH BIOVENTURES III B L.P.
GROUP MEMBERS: ABINGWORTH BIOVENTURES III C L.P.
GROUP MEMBERS: ABINGWORTH BIOVENTURES III EXECUTIVES L.P.
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-79884
FILM NUMBER: 05635129
BUSINESS ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Abingworth Management LTD
CENTRAL INDEX KEY: 0001291892
IRS NUMBER: 000000000
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
BUSINESS PHONE: 44 20 7534 1508
MAIL ADDRESS:
STREET 1: 38 JERMYN STREET
CITY: LONDON
STATE: X0
ZIP: SW1Y 6DN
SC 13G/A
1
sch13ga_13307.txt
SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS INC.
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
SCHEDULE 13G
(RULE 13D-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1 (b) (c),
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(b)
(AMENDMENT NO. 1 )*
Alnylam Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value per share
--------------------------------------------------------------------------------
(Title of Class of Securities)
02043Q107
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2004
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
================================================================================
=================== ==================
CUSIP NO. 02043Q107 13G PAGE 2 OF 13 PAGES
=================== ==================
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Management Limited
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)[_]
(b)[_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 shares
NUMBER OF -----------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,343,163 shares
EACH -----------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH: 0 shares
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,343,163 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,343,163 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.7%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 2 of 13 Pages
=================== ==================
CUSIP NO. 02043Q107 13G PAGE 3 OF 13 PAGES
=================== ==================
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III A L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)[_]
(b)[_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 shares
NUMBER OF -----------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,343,163 shares
EACH -----------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH: 0 shares
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,343,163 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,343,163 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.7%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 3 of 13 Pages
=================== ==================
CUSIP NO. 02043Q107 13G PAGE 4 OF 13 PAGES
=================== ==================
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III B L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)[_]
(b)[_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 shares
NUMBER OF -----------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,343,163 shares
EACH -----------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH: 0 shares
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,343,163 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,343,163 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.7%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 4 of 13 Pages
=================== ==================
CUSIP NO. 02043Q107 13G PAGE 5 OF 13 PAGES
=================== ==================
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III C L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)[_]
(b)[_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
ENGLAND
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 shares
NUMBER OF -----------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,343,163 shares
EACH -----------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH: 0 shares
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,343,163 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,343,163 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.7%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 5 of 13 Pages
=================== ==================
CUSIP NO. 02043Q107 13G PAGE 6 OF 13 PAGES
=================== ==================
================================================================================
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abingworth Bioventures III Executives L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a)[_]
(b)[_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 shares
NUMBER OF -----------------------------------------------------
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY 2,343,163 shares
EACH -----------------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON
WITH: 0 shares
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
2,343,163 shares
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,343,163 shares
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.7%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
================================================================================
Page 6 of 13 Pages
ITEM 1(A). NAME OF ISSUER:
---------------
Alnylam Pharmaceuticals, Inc. (the "Issuer")
ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
------------------------------------------------
300 Third Street, Cambridge, MA 02142.
ITEM 2(A). NAMES OF PERSONS FILING:
------------------------
Abingworth Management Limited ("Abingworth Management"), and
Abingworth Bioventures III A L.P. ("ABV III A"), Abingworth
Bioventures III B L.P. ("ABV III B"), Abingworth Bioventures III C
L.P. ("ABV III C") and Abingworth Bioventures III Executives L.P.
(ABV III Executives"), (collectively, the "Funds"). Abingworth
Management, the manager of the Funds, may be deemed to have sole
power to vote and sole power to dispose of shares of the Issuer
directly owned by the Funds. The persons named in this paragraph
are referred to individually herein as a "Reporting Person" and
collectively as the "Reporting Persons."
ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
------------------------------------------------------------
The address of the principal business office of Abingworth
Management, ABV III A, ABV III B, ABV III C and ABV III Executives
is c/o Abingworth Management Limited, Princess House, 38 Jermyn
Street, London, England SW1Y 6DN.
ITEM 2(C). CITIZENSHIP:
------------
Abingworth Management is a corporation organized under the laws of
England. ABV III A, ABV III B and ABV III C are limited
partnerships organized under the laws of England. ABV III
Executives is a limited partnership organized under the laws of
Delaware.
ITEM 2(D). TITLE OF CLASS OF SECURITIES:
-----------------------------
Common Stock, $0.01 par value per share ("Common Stock").
ITEM 2(E). CUSIP NUMBER:
-------------
02043Q107.
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS. 240.13D-1(B) OR
-------------------------------------------------------------
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
----------------------------------------------------------
(a) [_] Broker or Dealer registered under Section 15 of the
Securities Exchange Act of 1934 (the "Act").
(b) [_] Bank as defined in Section 3(a)(6) of the Act.
(c) [_] Insurance Company as defined in Section 3(a)(19) of the
Act.
(d) [_] Investment Company registered under Section 8 of the
Investment Company Act of 1940.
(e) [_] Investment Adviser in accordance with
ss.240.13d-1(b)(1)(ii)(E).
(f) [_] An employee benefit plan or endowment fund in accordance
with ss.240.13d-1(b)(1)(ii)(F).
(g) [_] A Parent Holding Company, in accordance with
ss.240.13d-1(b)(1)(ii)(G).
(h) [_] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act.
(i) [_] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the
Investment Company Act of 1940.
(j) [_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
None of the above.
ITEM 4. OWNERSHIP.
----------
(a) Amount Beneficially Owned: ABV III A is the record owner of
1,176,269 shares of Common Stock (the "ABV III A Shares") as of
December 31, 2004. ABV III B is the record owner of 718,037
shares of Common Stock (the "ABV III B Shares") as of December
31, 2004. ABV III C is the record owner of 430,112 shares of
Common Stock (the "ABV III C Shares") as of December 31, 2004.
ABV III Executives is the record owner of 18,745 shares of
Common Stock (the "ABV III Executive Shares") as of December
31, 2004. Abingworth Management, the manager of the Funds, may
be deemed to own beneficially all of the ABV III A Shares, the
ABV III B Shares, the ABV III C Shares and the ABV III
Executive Shares.
(b) Percent of Class: See Line 11 of cover sheets. The percentages
set forth on the cover sheets are calculated based on
20,085,590 shares of Common Stock reported to be outstanding as
of November 1, 2004 in the Issuer's most recently filed
Quarterly Statement on Form 10-Q, as adjusted pursuant to Rule
13d-3(d)(1).
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: See Line 5 of
cover sheets.
(ii) shared power to vote or to direct the vote: See Line 6 of
cover sheets.
(iii) sole power to vote or to direct the vote: See Line 7 of
cover sheets.
(iv) shared power to dispose or to direct the disposition of:
See Line 8 of cover sheets.
Each Reporting Person disclaims beneficial ownership of such
shares of Common Stock except for the shares, if any, such
Reporting Person holds of record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
---------------------------------------------
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
----------------------------------------------------------------
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
------------------------------------------------------------------
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
-------------------------------------------------------------
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
----------------------------------------------------------
Not applicable. The Reporting Persons expressly disclaim membership
in a "group" as used in Rule 13d-1(b)(ii)(J).
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
-------------------------------
Not applicable.
ITEM 10. CERTIFICATION.
--------------
By signing below each of the undersigned certify that, to the best
of its knowledge and belief, the securities referred to above were
not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
---------
After reasonable inquiry and to the best of its knowledge and belief, each
of the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: February 14, 2005
ABINGWORTH MANAGEMENT LIMITED
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III A L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III B L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III C L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III EXECUTIVES L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
Exhibit 1
---------
AGREEMENT
---------
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the
undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Alnylam Pharmaceuticals, Inc.
EXECUTED as a sealed instrument this 14th day of February, 2005.
ABINGWORTH MANAGEMENT LIMITED
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III A L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III B L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III C L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director
ABINGWORTH BIOVENTURES III EXECUTIVES L.P.
By: Abingworth Management Limited, its Manager
By: /s/James Abell
----------------------------------
James Abell
Executive Director